在帕金森病中通过大麻的旅程
Elaine Del-Bel1, Nubia Barros-Pereira2, Rafaela Ponciano de Moraes3
1Department of Basic and Oral Biology, School of Dentistry of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, SP, Brazil; National Institute for Science and Technology, Translational Medicine, University of Sao Paulo, Ribeirao Preto, SP Brazil; Center for Cannabinoid Research, Mental Health Building, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP Brazil.
International review of neurobiology
|July 19, 2024
概括
大麻二醇显示出治疗帕金森病症状的前景,提供神经保护. 需要更多的研究来证实其有效性和患者的最佳使用.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 大麻素研究 研究 大麻素研究
背景情况:
- 帕金森病 (PD) 是一种神经退行性疾病,治疗选择有限,副作用很大.
- 非运动性症状在PD中很普遍,影响患者的生活质量.
- Cannabidiol (CBD) 是一种非精神活性植物性大麻素,目前正在研究其治疗潜力.
研究的目的:
- 审查和综合有关使用大麻素作为帕金森病潜在治疗方法的证据.
- 专注于单独使用大麻素的研究.
- 评估与PD相关的大麻的神经保护,抗炎和抗氧化特性.
主要方法:
- 系统审查临床前和临床初步研究.
- 对研究大麻素对帕金森病模型和症状的影响的研究分析.
- 检查大麻二醇的药理机制和报告的结果.
主要成果:
- 临床前研究表明,在帕金森病模型中,大麻素的结果令人鼓舞.
- 大麻二醇显示出潜在的神经保护,抗炎和抗氧化作用.
- 初步证据表明,大麻素可以缓解PD的运动和非运动症状.
结论:
- 大麻二醇作为帕金森病的新疗法具有前景.
- 需要进一步的研究来克服与不同剂量,配方和方法相关的挑战.
- 大麻可能为患有帕金森病的人提供更好的生活质量.
相关概念视频
Parkinson's Disease: Treatment
244
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
244
Parkinson's Disease: Overview
517
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
517
Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
209
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
209
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K


